Long-term follow-up in common variable immunodeficiency: the pediatric-onset and adult-onset landscape.
CD21low B cells
autoimmunity
common variable immunodeficiency (CVID)
cytopenia
immune dysregulation
inborn errors of immunity
lymphoid proliferation
Journal
Frontiers in pediatrics
ISSN: 2296-2360
Titre abrégé: Front Pediatr
Pays: Switzerland
ID NLM: 101615492
Informations de publication
Date de publication:
2023
2023
Historique:
received:
16
12
2022
accepted:
07
02
2023
medline:
12
7
2023
pubmed:
12
7
2023
entrez:
12
7
2023
Statut:
epublish
Résumé
The primary aim of this study is to investigate the evolution of the clinical and laboratory characteristics during the time in a longitudinal cohort of pediatric-onset and adult-onset Common Variable Immunodeficiency (CVID) patients in order to identify early predictive features of the disease and immune dysregulation complications. This is a retrospective-prospective monocentric longitudinal study spanning from 1984 to the end of 2021. The data of pediatric-onset vs. adult-onset patients have been compared for immunological features and for infectious and non-infectious complications assessed at diagnosis and follow-up. Seventy-three CVID patients have been enrolled, with a mean of 10.0 years (SD ± 8.17) of prospective follow-up. At diagnosis, infections were observed in 89.0% of patients and immune dysregulation in 42.5% of patients. At diagnosis, 38.6% of pediatric-onset and 20.7% of adult-onset patients presented with only infections. Polyclonal lymphoid proliferation (62.1%) and autoimmunity (51.7%) were more prevalent in the adult-onset than in the pediatric-onset group (polyclonal lymphoid proliferation 52.3% and autoimmunity 31.8%, respectively). Enteropathy was present in 9.1% of pediatric-onset and 17.2% of adult-onset patients. The prevalence of polyclonal lymphoid proliferation increased during follow-up more in pediatric-onset patients (diagnosis 52.3%-follow-up 72.7%) than in adult-onset patients (diagnosis 62.1%-follow-up 72.7%). The cumulative risk to develop immune dysregulation increases according to the time of disease and the time of diagnostic delay. At the same age, pediatric-onset patients have roughly double the risk of having a complication due to immune dysregulation than adult-onset patients, and it increases with diagnostic delay. The analysis of lymphocyte subsets in the pediatric-onset group showed that CD21 low B cells at diagnosis may be a reliable prognostic marker for the development of immune dysregulation during follow-up, as the ROC curve analysis showed (AUC = 0.796). In the adult-onset group, the percentage of transitional B cells measured at diagnosis showed a significant accuracy (ROC AUC = 0.625) in identifying patients at risk of developing immune dysregulation. The longitudinal evaluation of lymphocyte subsets combined with clinical phenotype can improve the prediction of lymphoid proliferation and allow experts to achieve early detection and better management of such complex disorder.
Identifiants
pubmed: 37435172
doi: 10.3389/fped.2023.1125994
pmc: PMC10332319
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1125994Informations de copyright
© 2023 Carrabba, Salvi, Baselli, Serafino, Zarantonello, Trombetta, Pietrogrande, Fabio and Dellepiane.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Orphanet J Rare Dis. 2018 Nov 12;13(1):201
pubmed: 30419968
J Allergy Clin Immunol. 2014 Jul;134(1):116-26
pubmed: 24582312
J Clin Immunol. 2010 Sep;30(5):746-55
pubmed: 20437084
Int Arch Allergy Immunol. 2022;183(3):337-349
pubmed: 34619682
Blood. 2008 Jan 1;111(1):77-85
pubmed: 17898316
J Allergy Clin Immunol. 2017 Mar;139(3S):S1-S46
pubmed: 28041678
J Clin Immunol. 2007 May;27(3):308-16
pubmed: 17510807
J Allergy Clin Immunol. 2022 Jan;149(1):315-326.e9
pubmed: 34146579
Pediatr Allergy Immunol. 2010 Aug;21(5):852-8
pubmed: 20337966
Front Immunol. 2020 Feb 07;11:149
pubmed: 32117289
Front Neurol. 2018 Nov 30;9:1031
pubmed: 30555409
J Allergy Clin Immunol. 2023 Jan;151(1):70-80
pubmed: 36608984
J Allergy Clin Immunol Pract. 2016 Jan-Feb;4(1):38-59
pubmed: 26563668
Expert Rev Clin Immunol. 2014 Feb;10(2):183-6
pubmed: 24410535
Blood. 2008 Jul 15;112(2):277-86
pubmed: 18319398
Clin Immunol. 1999 Dec;93(3):190-7
pubmed: 10600329
Int Arch Allergy Immunol. 2020;181(3):228-237
pubmed: 31901904
Blood. 2012 Feb 16;119(7):1650-7
pubmed: 22180439
Front Immunol. 2022 Mar 11;13:857050
pubmed: 35359997
Nat Genet. 2005 Aug;37(8):829-34
pubmed: 16007086
J Pediatr. 1986 Jun;108(6):915-22
pubmed: 2423668
Immunol Rev. 2019 Jan;287(1):145-161
pubmed: 30565247
J Allergy Clin Immunol Pract. 2019 Jul - Aug;7(6):1763-1770
pubmed: 30776527
J Clin Immunol. 2019 Oct;39(7):678-687
pubmed: 31377970
Blood. 2020 Feb 27;135(9):656-667
pubmed: 31942606
Expert Rev Clin Immunol. 2020 Dec;16(12):1227-1235
pubmed: 33203275
J Allergy Clin Immunol. 2021 Nov;148(5):1332-1341.e5
pubmed: 33895260
Expert Rev Clin Immunol. 2019 Oct;15(10):1105-1113
pubmed: 31452405
J Clin Immunol. 2022 Oct;42(7):1508-1520
pubmed: 36198931
Curr Opin Pediatr. 2007 Dec;19(6):685-92
pubmed: 18025937
J Clin Immunol. 2017 Aug;37(6):592-602
pubmed: 28755066
J Clin Immunol. 2018 Jan;38(1):96-128
pubmed: 29226302
Front Immunol. 2018 Sep 10;9:2012
pubmed: 30250467
J Clin Immunol. 2022 Aug;42(6):1270-1279
pubmed: 35588029
Br J Haematol. 2009 Jun;145(6):709-27
pubmed: 19344423